Malignant and Noninvasive Skin Tumours in Renal Transplant Recipients
Background. Transplant recipients require immunosuppression to prevent graft rejection. This conveys an increased risk of malignancy, particularly skin tumours. There is a need for up-to-date data for the South of England. Method. Pathology records were reviewed for 709 kidney transplant recipien...
Saved in:
Main Authors: | , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2014-01-01
|
Series: | Dermatology Research and Practice |
Online Access: | http://dx.doi.org/10.1155/2014/409058 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
_version_ | 1832550389885435904 |
---|---|
author | Christopher D. Roche Joelle S. Dobson Sion K. Williams Mara Quante Joyce Popoola Jade W. M. Chow |
author_facet | Christopher D. Roche Joelle S. Dobson Sion K. Williams Mara Quante Joyce Popoola Jade W. M. Chow |
author_sort | Christopher D. Roche |
collection | DOAJ |
description | Background. Transplant recipients require immunosuppression to prevent graft rejection. This conveys an increased risk of malignancy, particularly skin tumours. There is a need for up-to-date data for the South of England. Method. Pathology records were reviewed for 709 kidney transplant recipients on immunosuppression at our hospital from 1995 to 2008. Skin tumours were recorded/analysed. Results. Mean age at transplant was 46 years. Mean length of follow-up was 7.2 years and total follow-up was 4926 person-years. 53 (7.5%) patients (39/458 (8.5%) males and 14/251 (5.6%) females) developed ≥1 skin malignancy. Cumulative incidences of 4.0%, 7.5%, and 12.2% were observed for those with <5, <10, and ≥10 years follow-up, respectively. The rate was 45 tumours per 1000 person-years at risk. Additionally, 21 patients (3.0%) only had noninvasive tumours. 221 malignant skin tumours were found: 50.2% were SCCs, 47.1% BCCs, and 2.7% malignant melanomas. Mean years to first tumour were 5.8. Mean number of tumours per patient was 4, with mean interval of 12 months. Conclusions. Despite changes in transplantation practice during the time since the last data were published in this region, these findings are similar to previous studies. This adds to the evidence allowing clinicians to inform patients in this region of their risk. |
format | Article |
id | doaj-art-f6c6184de1e544539bb8041635a35300 |
institution | Kabale University |
issn | 1687-6105 1687-6113 |
language | English |
publishDate | 2014-01-01 |
publisher | Wiley |
record_format | Article |
series | Dermatology Research and Practice |
spelling | doaj-art-f6c6184de1e544539bb8041635a353002025-02-03T06:07:01ZengWileyDermatology Research and Practice1687-61051687-61132014-01-01201410.1155/2014/409058409058Malignant and Noninvasive Skin Tumours in Renal Transplant RecipientsChristopher D. Roche0Joelle S. Dobson1Sion K. Williams2Mara Quante3Joyce Popoola4Jade W. M. Chow5St George’s, University of London, Cranmer Terrace, London SW17 0RE, UKSt George’s, University of London, Cranmer Terrace, London SW17 0RE, UKThe National Hospital for Neurology, 23 Queen Square, London WC1N 3BG, UKDepartment of Histopathology, Royal Sussex County Hospital, Eastern Road, Brighton BN2 5BE, UKDepartment of Renal Medicine and Transplantation, St George’s Healthcare NHS Trust, Blackshaw Road, London SW17 0QT, UKSt George’s, University of London, Cranmer Terrace, London SW17 0RE, UKBackground. Transplant recipients require immunosuppression to prevent graft rejection. This conveys an increased risk of malignancy, particularly skin tumours. There is a need for up-to-date data for the South of England. Method. Pathology records were reviewed for 709 kidney transplant recipients on immunosuppression at our hospital from 1995 to 2008. Skin tumours were recorded/analysed. Results. Mean age at transplant was 46 years. Mean length of follow-up was 7.2 years and total follow-up was 4926 person-years. 53 (7.5%) patients (39/458 (8.5%) males and 14/251 (5.6%) females) developed ≥1 skin malignancy. Cumulative incidences of 4.0%, 7.5%, and 12.2% were observed for those with <5, <10, and ≥10 years follow-up, respectively. The rate was 45 tumours per 1000 person-years at risk. Additionally, 21 patients (3.0%) only had noninvasive tumours. 221 malignant skin tumours were found: 50.2% were SCCs, 47.1% BCCs, and 2.7% malignant melanomas. Mean years to first tumour were 5.8. Mean number of tumours per patient was 4, with mean interval of 12 months. Conclusions. Despite changes in transplantation practice during the time since the last data were published in this region, these findings are similar to previous studies. This adds to the evidence allowing clinicians to inform patients in this region of their risk.http://dx.doi.org/10.1155/2014/409058 |
spellingShingle | Christopher D. Roche Joelle S. Dobson Sion K. Williams Mara Quante Joyce Popoola Jade W. M. Chow Malignant and Noninvasive Skin Tumours in Renal Transplant Recipients Dermatology Research and Practice |
title | Malignant and Noninvasive Skin Tumours in Renal Transplant Recipients |
title_full | Malignant and Noninvasive Skin Tumours in Renal Transplant Recipients |
title_fullStr | Malignant and Noninvasive Skin Tumours in Renal Transplant Recipients |
title_full_unstemmed | Malignant and Noninvasive Skin Tumours in Renal Transplant Recipients |
title_short | Malignant and Noninvasive Skin Tumours in Renal Transplant Recipients |
title_sort | malignant and noninvasive skin tumours in renal transplant recipients |
url | http://dx.doi.org/10.1155/2014/409058 |
work_keys_str_mv | AT christopherdroche malignantandnoninvasiveskintumoursinrenaltransplantrecipients AT joellesdobson malignantandnoninvasiveskintumoursinrenaltransplantrecipients AT sionkwilliams malignantandnoninvasiveskintumoursinrenaltransplantrecipients AT maraquante malignantandnoninvasiveskintumoursinrenaltransplantrecipients AT joycepopoola malignantandnoninvasiveskintumoursinrenaltransplantrecipients AT jadewmchow malignantandnoninvasiveskintumoursinrenaltransplantrecipients |